Tercica Report issue

Contributed to NME For profit Phase 3
Founded: Brisbane CA United States (2002)
Status: Acquired by Ipsen (2008)

Organization Overview

First Clinical Trial
2007
NCT00516386
First Marketed Drug
2005
mecasermin (increlex)
First NDA Approval
2005
mecasermin (increlex)
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree